 |
|
|
| |
Prediction of Renal OAT1 and OAT3 Inhibition by Cabotegravir Using PBPK Modelling
|
| |
| |
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
Kunal S. Taskar,1 Aarti Patel,1 Simon J. Cozens,1 Helen Tracey,1 Susan Ford,2 Kelong Han,2 William Spreen,3 Mark Baker,4 Parul Patel3
1GlaxoSmithKline, Ware, UK; 2GlaxoSmithKline, Research Triangle Park, NC, USA; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4ViiV Healthcare, Nyon, Switzerland
|
| |
|
|
|
|
|
